891 related articles for article (PubMed ID: 34787500)
21. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
22. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
23. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
24. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
Tong ZQ; Wu DY; Liu D; Dong M
Eur J Clin Pharmacol; 2021 Aug; 77(8):1079-1088. PubMed ID: 33564898
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
Zhang R; Zhu J; Liu Y; Xin Y; Wang Y; Niu K; Wei H
Medicine (Baltimore); 2021 Mar; 100(10):e19713. PubMed ID: 33725808
[TBL] [Abstract][Full Text] [Related]
26. Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials.
Xu Z; Liang J; Fu R; Yang L; Xin Chen Y; Ren W; Lu Y; Qiu X; Gu Q
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):640-651. PubMed ID: 37563075
[TBL] [Abstract][Full Text] [Related]
27. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials.
Zhou GW; Xiong Y; Chen S; Xia F; Li Q; Hu J
Medicine (Baltimore); 2016 Aug; 95(35):e4611. PubMed ID: 27583876
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
30. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
31. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
[TBL] [Abstract][Full Text] [Related]
33. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
34. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
35. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
36. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
37. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
38. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
39. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
40. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
